Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.41 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.31 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26287140 | 0.94 | POLRMT (0.42) | POLRMTDOT1LRIPK1TMPRSS2 | |
| SCHEMBL26281133 | 0.93 | POLRMT (0.39) | POLRMTDOT1LALDH1A1KMT2A | |
| SCHEMBL26283409 | 0.93 | POLRMT (0.39) | POLRMTDOT1LALDH1A1KMT2A | |
| SCHEMBL23818938 | 0.92 | POLRMT (0.41) | POLRMTDOT1LRIPK1TMPRSS2 | |
| SCHEMBL26283806 | 0.92 | POLRMT (0.41) | POLRMTDOT1LRIPK1 | |
| SCHEMBL26285466 | 0.91 | POLRMT (0.39) | POLRMTDOT1L | |
| SCHEMBL26287724 | 0.91 | POLRMT (0.40) | POLRMTDOT1L | |
| SCHEMBL26280537 | 0.91 | POLRMT (0.39) | POLRMTDOT1L | |
| SCHEMBL26287683 | 0.90 | POLRMT (0.39) | POLRMTDOT1LRIPK1 | |
| SCHEMBL26282444 | 0.90 | POLRMT (0.40) | POLRMTDOT1LRIPK1TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20210284669-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | POLRMT 535/4885DOT1L 3143/4885ALDH1A1 1459/4885 |
| US-20210284669-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, SNRPA | POLRMT 352/4885DOT1L 3736/4885ALDH1A1 756/4885 |
| US-11767337-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | POLRMT 535/4885DOT1L 3143/4885ALDH1A1 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.